A federal judge in Delaware has overturned a jury’s verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc.

The drug was approved in India in November this year and is the “first” to be approved in eight years for the management of this infection here, Mylan added.

Today, The Medicines Patent Pool and Gilead Sciences, Inc reported signing of a licensing agreement on the expansion of access to Bictegravir.